BioPlus Acquisition Corp
NASDAQ:BIOS
Intrinsic Value
BioPlus Acquisition Corp. operates as a blank check company. [ Read More ]
The intrinsic value of one BIOS stock under the Base Case scenario is 12.025 USD. Compared to the current market price of 10.795 USD, BioPlus Acquisition Corp is Undervalued by 10%.
Valuation Backtest
BioPlus Acquisition Corp
Run backtest to discover the historical profit from buying and selling BIOS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BioPlus Acquisition Corp
Current Assets | 196.8k |
Cash & Short-Term Investments | 2.5k |
Other Current Assets | 194.4k |
Non-Current Assets | 138.4m |
Long-Term Investments | 138.4m |
Current Liabilities | 2m |
Accrued Liabilities | 408.8k |
Short-Term Debt | 250k |
Other Current Liabilities | 1.3m |
Non-Current Liabilities | 14.8m |
Long-Term Debt | 5m |
Other Non-Current Liabilities | 9.8m |
Earnings Waterfall
BioPlus Acquisition Corp
Revenue
|
0
USD
|
Operating Expenses
|
-2.2m
USD
|
Operating Income
|
-2.2m
USD
|
Other Expenses
|
8m
USD
|
Net Income
|
5.8m
USD
|
Free Cash Flow Analysis
BioPlus Acquisition Corp
BIOS Profitability Score
Profitability Due Diligence
BioPlus Acquisition Corp's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
BioPlus Acquisition Corp's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
BIOS Solvency Score
Solvency Due Diligence
BioPlus Acquisition Corp's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
BioPlus Acquisition Corp's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOS Price Targets Summary
BioPlus Acquisition Corp
According to Wall Street analysts, the average 1-year price target for BIOS is 20 USD .
Shareholder Return
BIOS Price
BioPlus Acquisition Corp
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -1% |
Market Capitalization | 209.1m USD |
Shares Outstanding | 19 367 500 |
Percentage of Shares Shorted | 0.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioPlus Acquisition Corp. operates as a blank check company. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2021-12-03. The firm is formed for the purpose effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The firm has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The firm intends to focus its search on companies in the life sciences industry. The firm has not commenced any operations nor generated any revenue.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOS stock under the Base Case scenario is 12.025 USD.
Compared to the current market price of 10.795 USD, BioPlus Acquisition Corp is Undervalued by 10%.